From black magic to science: Understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies

Clinical and Experimental Immunology

Volumn 124, Issue 2, 2001, Pages 169-171

  Patel, S Y ^a   Kumararatne, D S ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; Dermatomyositis; Immunoglobulin; Inflammatory; Intravenous; Myopathy; Polymyositis

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CORTICOSTEROID; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANIMAL MODEL; AUTOIMMUNITY; CLINICAL TRIAL; COMPETITIVE INHIBITION; COMPLEMENT INHIBITION; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG MECHANISM; GUINEA PIG; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; MYOPATHY; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

ANIMALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MYOSITIS; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL;

EID: 0034960001     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01565.x     Document Type: Review

References (31)

1. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
2. Intravenous immunoglobulin therapy for rheumatic diseases
3. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases
4. IGIV in neurology - Evidence and recommendations
5. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies
6. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American Group on Hemostasis and Thrombosis
7. High-dose intravenous gammaglobulin for Kawasaki disease
8. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg)
9. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
10. Idiopathic thrombocytopenic purpura (ITP): Immunomodulation by intravenous immunoglobulin (IVIg)
11. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura
12. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect
13. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes
14. Immunoglobulins and the regulation of autoimmunity through the immune network
15. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR)
16. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies
17. Modulation of complement-mediated immune damage by intravenous immune globulin
18. Pediatric autoimmune cardiovascular disease
19. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg)
20. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
21. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype
22. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing antimyosin antibody and by blocking complement deposition
23. Myositis: Immunologic contributions to understanding cause pathogenesis and therapy
24. Cellular immune mechanisms in inflammatory myopathies
25. Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis
26. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
27. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease
28. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy
29. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
30. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin
31. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sIL-2R levels